Document is current

Article History

Received: 20 September 2024

Accepted: 3 February 2025

First Online: 14 February 2025

Declarations

:

: Not applicable.

: •Ya Hwee Tan: Travel support from Gilead. •Dok Hyun Yoon: Honoraria from Roche, Janssen, Amgen, BMS, Kirin, Boryung and Takeda; Consulting/advisory role at Roche, Janssen, Amgen, BMS, Novartis, Abclone, GI cell, GC cell and Pharos Bio; Research funding from Samyang, Kirin, Roche, Janssen, Boryung. •Andrew J Davies: Research funding and support from Celgene, Roche, Kite, GSK, Janssen, Karyopharm Therapeutics, Acerta Pharma/AstraZeneca, and ADC Therapeutics; Advisory board role at Celgene, Roche, Kite, Genmab, Karyopharm Therapeutics, Sobi, Incyte, and AbbVie; Honorarium from Celgene, Roche, Kite, Genmab, Janssen, Acerta Pharma/AstraZeneca, and ADC Therapeutics; Travel support from Celgene and Roche. •Christian Buske: Honoraria from Roche/Genentech, Janssen, BeiGene, Novartis, Pfizer, Incyte, AbbVie, Gilead Sciences, Celltrion, MorphoSys, Regeneron, Sobi, Lilly; Consulting or advisory role at Gilead Sciences, Janssen, Roche, Pfizer, BeiGene, Celltrion, AbbVie, Incyte, Regeneron, MorphoSys, Novartis, Sobi, Lilly; Speakers’ bureau for Roche, Janssen, BeiGene, Celltrion, AbbVie, Pfizer, Gilead Sciences, Novartis, Gilead, Incyte, Pfizer, MorphoSys, Sobi, Lilly; Research funding from Roche/Genentech, Janssen, Celltrion, MSD, Pfizer, Amgen, Bayer. •Yang Liang Boo: Nothing to disclose. •Nagavalli Somasundaram: Nothing to disclose. •Francesca Lim: Nothing to disclose. •Shin Yeu Ong: Nothing to disclose. •Anand Jeyasekharan: Consultancy fees from DKSH/Beigene, Roche, Gilead, Turbine Ltd, AstraZeneca, Antengene, Janssen, MSD and IQVIA; Research funding from Janssen and AstraZeneca. •Koji Izutsu: Consulting fees from AstraZeneca, Ono Pharmaceutical, Mitsubishi Tanabe, Eisai, Chugai, Bristol Myers Squibb, AbbVie, Takeda, Zenyaku, Genmab, Kyowa Kirin, MSD, Carna Biosciences, Novartis, Yakult, Nihon Shinyaku, Novartis, Beigene; Honoraria from AstraZeneca, Ono Pharmaceutical, Eisai, Chugai, Janssen, Symbio, Bristol Myers Squibb, Daiichi Sankyo, Otsuka, AbbVie, Takeda, Eli Lilly, Genmab, Kyowa Kirin, MSD, Astellas, Pfizer, Meiji Seika Pharma, Novartis, Nihon Kayaku, Gilead; Research funding from Chugai, Bristol Myers Squibb, Incyte, Genmab, LOXO Oncology, Daiichi Sankyo, BeiGene, AbbVie, AstraZeneca, Regeneron, Yakult, Otsuka, Novartis, Pfizer, MSD, Bayer, Kyowa Kirin, Eisai, Janssen, Ono Pharmaceutical, Gilead, Astellas Amgen. •Won Seog Kim: Grant/research support from Sanofi, BeiGene, Boryong, Roche, Kyowa Kirin, Donga. •Jason Yongsheng Chan: Consultation/Speaker’s Bureau: Antengene, Takeda, AstraZeneca, Novartis, Roche, MSD, Specialised Therapeutics, DKSH/Beigene, Janssen, AbbVie; Grant/Research support: SymBio Pharmaceuticals, Scinnohub Pharmaceuticals, ArcherDX/Invitae, Miltenyi Biotec, STEMCELL Technologies, MGI Technologies, BGI Research, Twist Biosciences, Agilent Technologies, Illumina, BioSyngen, NovogeneAIT, Phillips; Travel support: AstraZeneca, Janssen, Amgen.